New Research In
Articles by Topic
- Agricultural Sciences
- Applied Biological Sciences
- Biophysics and Computational Biology
- Cell Biology
- Developmental Biology
- Environmental Sciences
- Immunology and Inflammation
- Medical Sciences
- Plant Biology
- Population Biology
- Psychological and Cognitive Sciences
- Sustainability Science
- Systems Biology
广东快乐十分稳赢200:Oncogenic mutations at the EGFR ectodomain structurally converge to remove a steric hindrance on a kinase-coupled cryptic epitope
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
EGFR cancer mutations display an astonishing tissue-specific asymmetry: in lung cancer, mutations target the intracellular kinase (KD), while in glioblastomas (GBMs), a variety of missense clusters and deletions concentrate at the ectodomain (ECD). Intriguingly, GBM-activating mutations share a paradoxical preference for inhibitors that bind the inactive kinase. By integrating simulations, small-angle X-ray scattering, and GBM models, we demonstrate that ECD mutants converge to a transition state characterized by a cryptic epitope, allosterically coupled to an intermediate kinase, and synergistically blocked by antibodies and inhibitors. Our findings indicate that apparently heterogeneous aberrations remove a similar steric restrain on KD activation. The diversity of structural tricks in ECD mutants to achieve the same conformational state constitutes a potent example of molecular mimicry and convergence.
Epidermal growth factor receptor (EGFR) signaling is initiated by a large ligand-favored conformational change of the extracellular domain (ECD) from a closed, self-inhibited tethered monomer, to an open untethered state, which exposes a loop required for strong dimerization and activation. In glioblastomas (GBMs), structurally heterogeneous missense and deletion mutations concentrate at the ECD for unclear reasons. We explore the conformational impact of GBM missense mutations, combining elastic network models (ENMs) with multiple molecular dynamics (MD) trajectories. Our simulations reveal that the main missense class, located at the I-II interface away from the self-inhibitory tether, can unexpectedly favor spontaneous untethering to a compact intermediate state, here validated by small-angle X-ray scattering (SAXS). Significantly, such intermediate is characterized by the rotation of a large ECD fragment (N-TR1), deleted in the most common GBM mutation, EGFRvIII, and that makes accessible a cryptic epitope characteristic of cancer cells. This observation suggested potential structural equivalence of missense and deletion ECD changes in GBMs. Corroborating this hypothesis, our FACS, in vitro, and in vivo data demonstrate that entirely different ECD variants all converge to remove N-TR1 steric hindrance from the 806-epitope, which we show is allosterically coupled to an intermediate kinase and hallmarks increased oncogenicity. Finally, the detected extraintracellular coupling allows for synergistic cotargeting of the intermediate with mAb806 and inhibitors, which is proved herein.
- ?1To whom correspondence may be addressed. Email: , , , or .
Author contributions: L.O., E.L., F.B.F., and M.O. designed research; L.O. conceived the original idea; L.O., A.H.T., R.L., A.D.P., A.H., T.N.C., and I.B.-H. performed research; T.N.C., P.B., and A.M.S. contributed new reagents/analytic tools; A.H.T., R.L., A.D.P., T.N.C., and I.B.-H. assisted with experiments; L.O., F.B.F., and M.O. supervised the experiments; L.O., A.H.T., R.L., J.G., A.D.P., T.N.C., P.B., I.B.-H., E.L., W.K.C., F.B.F., and M.O. analyzed data; and L.O. and J.G. wrote the paper.
Reviewers: M.S.P.S., University of Oxford; and F.M.W., Massachusetts Institute of Technology.
Conflict of interest statement: A.M.S. is an inventor on patents related to mAb806 and has received research support from Abbvie, the National Health and Medical Research Council, and the Cancer Council Victoria. A.M.S. is also a consultant with Life Science Pharmaceuticals. A.M.S., F.B.F., and W.K.C. are inventors on US Patent 9,023,356 on a treatment method using EGFR antibodies and src inhibitors in related formulations.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1821442116/-/DCSupplemental.
Published under the PNAS license.